SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-510578-25-00

Acronym

RG_18-205

Enrollment

407

Registered

2024-11-06

Start date

2021-11-05

Completion date

Unknown

Last updated

2025-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-wingless-type (WNT) (Groups 3 and 4) medulloblastoma, with at least one additional high risk feature

Brief summary

Event-free survival

Detailed description

Overall survival, Progression-free survival

Interventions

DRUGVINCRISTINE SULFATE

DRUGTEMOZOLOMIDE

DRUGLomustine caps 10 mg

DRUGCISPLATIN

DRUGTHIOTEPA

DRUGLOMUSTINE

DRUGCARBOPLATIN

DRUGCYCLOPHOSPHAMIDE

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Event-free survival	—

Secondary

Measure	Time frame
Overall survival, Progression-free survival	—

Countries

Austria, Belgium, Czechia, Denmark, Finland, Germany, Italy, Netherlands, Norway, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026